- Cabometyx/Opdivo combination data in first-line renal cell carcinoma succeeded in its pivotal trial and achieved FDA approval, but figures to accomplish little for both companies.
- Analysts point to the stronghold Opdivo and Yervoy have within the first-line indication and the lack of duration in CheckMate-9ER data.
- Meanwhile, Cabometyx remains the go-to drug in second-line patients, procuring hundreds of millions of dollars per year, and Exelixis has stockpiled over $1.2B+ in cash.
- Furthermore, the company continues to progress on other Cabometyx monotherapy indications, as well as many other pipeline candidates.
- Exelixis remains an oncology powerhouse trading at an attractive price.
For further details see:
Cabo/Opdivo Combo Unlikely To Move Needle, But Exelixis Remains Attractive